FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
23/07/2026
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Tipo de processo
Eventos registrados
Atualização mais recente
Classificação
Tipo de marca
Classes Nice
Data de depósito
Data de registro
Data de expiração
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
Última transação
Escritório responsável
Código da situação
Cadastro oficial
Código do desenho
Tipo de titular
Localização do titular
Examinador
Unidade examinadora
Localização atual
Titulares
Representantes
Nicole M. Meyer Dickinson Wright PLLC
Classes Nice
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations and substances and therapeutic pharmaceuticals for diseases, traumatic injury, perioperative care, and inflammation related to the eye; pharmaceutical preparations, substances and treatments in the nature of eye drops, solutions, gels, films impregnated with preparations for the treatment of ocular and dermal conditions, sterilized dressings, sprays, lubricants, and ointments used for treatment for ocular diseases and conditions; pharmaceutical preparations, substances and treatments in the nature of eye drops, solutions, gels, lubricants, and ointments used for treatment for ocular diseases, ocular surface diseases and dry eye disease; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations, substances and treatments in the nature of solutions, gels, films impregnated with preparations for the treatment of ocular and dermal conditions, sterilized dressings, sprays, and ointments used for treatment for dermal diseases and conditions; pharmaceutical preparations, substances and treatments in the nature of solutions, gels, films impregnated with preparations for the treatment of scars, wounds and orthopaedic conditions, and for use in medical aesthetics treatments, sterilized dressings, sprays, and ointments used for treatment for scar prevention, wound healing, medical aesthetics and orthopaedic conditions; therapeutic preparations and substances, namely, eye drops, ocular lubricants, solutions, gels, films impregnated with preparations for the treatment of ocular diseases, ocular conditions, ocular surface diseases and dry eye disease, sterilized dressings, sprays, lubricants, and ointments for the treatment of ocular diseases, ocular conditions, ocular surface diseases and dry eye disease; gels for medical eye care; therapeutic gels for medical eye care; gel and liquid drops, sprays, films for use as a delivery agent for drugs and for therapeutic pharmaceuticals, suspensions in the nature of pharmaceutical preparations and therapeutic pharmaceuticals for the treatment of ocular diseases and conditions, and substances in the nature of pharmaceutical preparations and therapeutic pharmaceuticals for the treatment of ocular diseases and conditions; gels, suspensions, and liquids in the nature of pharmaceutical preparations and therapeutic pharmaceuticals for the treatment of ocular diseases and conditions; gels, suspensions, liquids, and lubricants in the nature of pharmaceutical preparations and therapeutic preparations for the treatment of eye conditions and diseases; tear film substitutes to provide lubrication, provide protection, support homeostasis, and for use as a delivery agent for drugs and supplements in the treatment of ocular conditions; tear film substitutes to provide lubrication, provide protection, support homeostasis, and for use as a delivery agent for drugs and supplements for the treatment of eye conditions and diseases; gels, suspensions, liquids, and lubricants in the nature of pharmaceutical preparations and therapeutic preparations for the treatment of eye conditions, namely, glaucoma, cataracts, amblyopia, age-related macular degeneration and diabetes-related retinopathy; gels, suspensions in the nature of pharmaceutical preparations and therapeutic pharmaceuticals, and liquids for medical and therapeutic use, namely, for treating eye diseases, treating traumatic eye injury, and used in perioperative eye care; eye drops; eye ointment for medical use; medicated eye-washes; eye lotions for medical use; lubricating eye drops; medicated liquids for the treatment of ocular diseases and conditions; medicated ocular lubricants; tear film substitutes being pharmaceutical preparations for the treatment of ocular diseases, injuries and conditions; tear substitutes, namely, artificial tears for ocular diseases and conditions; tear film substitutes, being pharmaceutical preparations in the form of eye drops, solutions, gels, sprays, lubricants, ointments and artificial tears for treatment of ocular diseases and conditions
Classe 42
Scientific and technological services and research and design relating thereto, namely, scientific research in the field of treatment of eye diseases, injuries and conditions, treatment of dermal diseases, injuries and conditions, and in the field of biomaterials science; industrial scientific analysis and research services in the fields of eye care products and wound care products; product research and development services; scientific and technological services and research services relating thereto, namely, scientific research in the field of treatment of eye diseases, eye injuries and eye conditions, treatment of dermal diseases, injuries and conditions, and in the field of biomaterials science; scientific research services for medical, biomedical and therapeutic purposes in the fields of ocular surface diseases, dry eye diseases, ocular surface injury, corneal wounds, glaucoma; medical and bioscience research services in the fields of ocular surface diseases, dry eye diseases, ocular surface injury, corneal wounds, glaucoma; biomedical research services; scientific research and development services relating to ocular diseases, treatment and conditions; research and development services relating to orthopaedics; scientific research and development services relating to dermatology; scientific research and development services relating to dermal applications, such as scar prevention, wound healing, medical aesthetics; scientific research and development services relating to the treatment of diseases and conditions; scientific research services relating to the treatment of eye diseases and conditions; therapeutic research services, namely, scientific research in the field of eye diseases and eye injury; advisory, consultancy and information services relating to all the aforesaid.
Histórico de despachos e eventos da marca no USPTO.
50 publicações encontradas
FINAL DECISION TRANSACTION PROCESSED BY IB
23/07/2026
FINAL DISPOSITION NOTICE SENT TO IB
06/07/2026
FINAL DISPOSITION PROCESSED
06/07/2026
NEW REPRESENTATIVE AT IB RECEIVED
07/05/2026
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
30/03/2026
NOTICE OF REGISTRATION CONFIRMATION EMAILED
30/12/2025
REGISTERED-PRINCIPAL REGISTER
30/12/2025
NEW REPRESENTATIVE AT IB RECEIVED
29/11/2025
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/11/2025
PUBLISHED FOR OPPOSITION
11/11/2025
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/11/2025
APPROVED FOR PUB - PRINCIPAL REGISTER
10/10/2025
EXAMINER'S AMENDMENT ENTERED
10/10/2025
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
10/10/2025
EXAMINERS AMENDMENT E-MAILED
10/10/2025
EXAMINERS AMENDMENT -WRITTEN
10/10/2025
TEAS/EMAIL CORRESPONDENCE ENTERED
10/09/2025
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/09/2025
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/09/2025
NOTIFICATION OF NON-FINAL ACTION E-MAILED
11/03/2025
NON-FINAL ACTION E-MAILED
11/03/2025
NON-FINAL ACTION WRITTEN
11/03/2025
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
08/02/2025
ASSIGNED TO EXAMINER
04/02/2025
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
22/01/2025
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
22/01/2025
TEAS/EMAIL CORRESPONDENCE ENTERED
09/01/2025
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/01/2025
TEAS REQUEST FOR RECONSIDERATION RECEIVED
09/01/2025
NOTIFICATION OF FINAL REFUSAL EMAILED
09/07/2024
FINAL REFUSAL E-MAILED
09/07/2024
FINAL REFUSAL WRITTEN
09/07/2024
TEAS/EMAIL CORRESPONDENCE ENTERED
04/06/2024
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/06/2024
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/06/2024
REFUSAL PROCESSED BY IB
03/01/2024
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
08/12/2023
REFUSAL PROCESSED BY MPU
05/12/2023
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
05/12/2023
NON-FINAL ACTION WRITTEN
04/12/2023
ASSIGNED TO EXAMINER
28/11/2023
TEAS CHANGE OF CORRESPONDENCE RECEIVED
31/10/2023
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
31/10/2023
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
31/10/2023
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
31/10/2023
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
31/10/2023
TEAS CHANGE OF OWNER ADDRESS RECEIVED
31/10/2023
APPLICATION FILING RECEIPT MAILED
29/08/2023
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
25/08/2023
SN ASSIGNED FOR SECT 66A APPL FROM IB
24/08/2023
Proteção contínua da sua marca
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.